UCB S.A.
UCB
株式のランク
#496
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
株価
$258.70
時価総額
$49.32B
変化（1日）
6.29%
変化（1年）
-12.28%
国
BE
取引 UCB S.A. (UCB)
カテゴリー
Healthcare
UCB S.A.（UCB）の発行済株式数
June 2026 時点の発行済株式数 0.00
UCB S.A. の最新の財務報告および株価によると、現在の発行済株式数は 0.00 です。December 2023 の終わりには、同社は 189.69M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
UCB S.A.（UCB）の発行済株式数の履歴（2002 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 189.89M | 0.10% |
| 2023 | 189.69M | 0.04% |
| 2022 | 189.62M | 0.34% |
| 2021 | 188.97M | -0.03% |
| 2020 | 189.04M | 0.97% |
| 2019 | 187.22M | -0.67% |
| 2018 | 188.48M | 0.11% |
| 2017 | 188.28M | -0.04% |
| 2016 | 188.37M | -1.94% |
| 2015 | 192.08M | 0.85% |
| 2014 | 190.46M | 4.56% |
| 2013 | 182.16M | 1.61% |
| 2012 | 179.28M | -6.39% |
| 2011 | 191.51M | 6.31% |
| 2010 | 180.15M | -0.02% |
| 2009 | 180.18M | 0.01% |
| 2008 | 180.17M | 0.00% |
| 2007 | 180.17M | 24.79% |
| 2006 | 144.38M | 0.60% |
| 2005 | 143.51M | -0.65% |
| 2004 | 144.45M | -1.02% |
| 2003 | 145.93M | -19.00% |
| 2002 | 180.17M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
